๐Ÿ›’ Your Cart

๐Ÿš€ Free shipping on orders over $200  |  99%+ Purity Guaranteed  |  Same-Day Dispatch Before 2PM EST
๐Ÿ“ US-Based Research Peptide Supplier  |  info@truetide.com
โ˜€๏ธ Melanocortin Research CAS: 75921-69-6 โœ“ 99%+ Purity

MT-1 (Melanotan I)
Afamelanotide โ€” Linear ฮฑ-MSH Analogue

โ˜…โ˜…โ˜…โ˜…โ˜…4.8 / 5  ยท  MC1R-selective, FDA-approved reference compound

Select Size

$75
10mg
โœ“
99%+ purity, independently verified by HPLC & mass spectrometry
โ„
Lyophilized vials โ€” shipped with cold pack, stable at โˆ’20ยฐC long term
๐Ÿ“„
Certificate of Analysis included with every order
๐Ÿšš
Same-day dispatch on orders before 2PM EST
๐Ÿ”’
Discreet, unmarked packaging โ€” research-grade handling
โš ๏ธ For Research Use Only. MT-1 (Melanotan I) is not approved for human consumption or therapeutic use. This product is sold exclusively as a research chemical for in vitro and laboratory research only.

What is Melanotan I?

Melanotan I (Afamelanotide, CUV1647) is a linear synthetic ฮฑ-MSH analogue with [Nleโด, D-Pheโท] substitutions that enhance MC1R binding affinity and metabolic stability. Unlike the cyclic Melanotan II, MT-1 is highly selective for MC1R, making it the preferred research tool for isolated melanocortin-1 receptor studies. It is FDA-approved (as Scenesseยฎ) for prevention of phototoxicity in erythropoietic protoporphyria.

CAS 75921-69-6 | MW 1646.9 Da

MC1R Selectivity

High selectivity for melanocortin-1 receptor vs MT-II which activates MC3R/MC4R broadly. Key for receptor-specific research.

Melanin Induction

Activates eumelanin synthesis pathway via MC1R-cAMP-PKA-MITF cascade. Produces photoprotective dark melanin.

Photoprotection

Clinical data demonstrates MT-1 implants reduce phototoxic reactions in EPP patients โ€” the basis of FDA approval.

Anti-inflammatory

MC1R activation has anti-inflammatory effects in skin โ€” distinct from MC3R-mediated pathways activated by MT-II.

FDA Approval: EPP Phase 3 Trial

Langendonk et al. demonstrated afamelanotide implants significantly reduced phototoxic reactions and improved quality of life in EPP patients โ€” leading to FDA approval in 2019.

N Engl J Med. 2015;373(1):48โ€“59

MC1R Selectivity Studies

Bednarek et al. established Melanotan I as the most MC1R-selective non-peptide-comparable reference, contrasting its linear structure with cyclic MT-II across all five MC receptor subtypes.

Biochemistry. 1999;38(47):15522โ€“15527

Skin Cancer Photoprotection Research

MT-1 increased melanin index and reduced UV-induced DNA damage in Fitzpatrick skin type I-II subjects, supporting photoprotection research applications.

J Invest Dermatol. 2006;126(7):1536โ€“1542

Research Dosing Data

EPP clinical dose: 16mg biodegradable implant (Scenesse). Research SC protocols use 0.16โ€“1.6 mg doses. In vitro MC1R studies: 1โ€“100 nM. Melanin quantification (absorbance/imaging), MC1R binding assay, and cAMP production are standard endpoints. Compare directly to MT-II for receptor subtype differentiation studies.

Selectivity Note: MT-1 is the appropriate reference when isolating MC1R effects from MC3R/MC4R confounders present with MT-II.
Full NameMelanotan I (Afamelanotide)
CAS Number75921-69-6
Molecular Weight1646.9 Da
SelectivityMC1R preferred
FDA StatusApproved (Scenesse) for EPP
Purityโ‰ฅ99% by HPLC
AppearanceWhite lyophilized powder
Storageโˆ’20ยฐC, desiccated